医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

腫瘍学

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

2021年02月18日

Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients

バイオテクノロジーヘルスケア外科病院腫瘍学臨床試験製薬遺伝学　 TimeLine: Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients

2021年02月15日

Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv in Patients with Previously Treated Advanced Urothelial Cancer Seagen and Astellas Announce Phase Trial Results Demonstrating Survival Advantage of PADCEV

2021年02月13日

Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy

Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv from PADCEV Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy Seagen and Astellas Announce Presentation of Results

2021年02月13日

Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据

Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据

2021年02月12日

Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

2021年02月11日

Rhizen Pharmaceuticals、提携先に提供した資産のUmbralisib（UKONIQ™）が米国FDAより再発性／難治性のMZLおよびFLの成人患者の治療薬として迅速承認を取得と発表

Rhizen Pharmaceuticals、提携先に提供した資産のUmbralisib（UKONIQ™）が米国FDAより再発性／難治性のMZLおよびFLの成人患者の治療薬として迅速承認を取得と発表

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: FL MZL Rhizen Pharmaceuticals UKONIQ Umbralisib

2021年02月11日

Rhizen Pharmaceuticals AG宣布其合作资产Umbralisib (UKONIQ™)已获得美国FDA加速核准，用于复发或难治MZL和FL成人患者

Rhizen Pharmaceuticals AG宣布其合作资产Umbralisib (UKONIQ™)已获得美国FDA加速核准，用于复发或难治MZL和FL成人患者

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: AG宣布其合作资产Umbralisib Rhizen Pharmaceuticals UKONIQ 已获得美国FDA加速核准或难治MZL和FL成人患者

2021年02月10日

Genetron Health’s Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China

Genetron Health’s Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China

バイオテクノロジーヘルスケアヘルス一般腫瘍学製薬　 TimeLine: Genetron Health’s Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China

2021年02月09日

Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug into Clinical Trials

Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug into Clinical Trials

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: $56M USD B Drug Drug Farm Closes Financing for Advancement of Lead Hepatitis into Clinical Trials

2021年02月09日